Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/28174487 below:

CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial

Affiliations

• ¹ Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
• ² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ³ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ⁴ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ⁵ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

• PMID: 28174487
• PMCID: PMC5242445
• DOI: 10.21147/j.issn.1000-9604.2016.06.05

Item in Clipboard

Fangqi Liu et al. Chin J Cancer Res. 2016 Dec.

• ¹ Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
• ² Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ³ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ⁴ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
• ⁵ Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

• PMID: 28174487
• PMCID: PMC5242445
• DOI: 10.21147/j.issn.1000-9604.2016.06.05

Item in Clipboard

Objective: The aim of this prospective, single-arm phase II trial was to confirm the safety and efficacy of neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX) for patients with operable locally advanced colon cancer (CC).

Methods: Patients with computed tomography-defined T4 or lymph node-positive CCs were enrolled. After radiological staging, patients were treated with at least 2 cycles of NAC consisting of 130 mg/m² oxaliplatin on d 1, plus 1,000 mg/m² capecitabine twice daily for 14 d every 3 weeks, followed by surgery, and then with the rest cycles of adjuvant chemotherapy. Radiological response was evaluated after 2 cycles of NAC. Tumor response, treatment toxicity, and surgical complications were recorded. The pathological response to therapy was evaluated according to the tumor regression grade (TRG) score. The primary endpoint was pathologic tumor response. This trial is registered in ClinicalTrials.gov (No: NCT02415829).

Results: Forty-seven patients were enrolled in the study. Forty-two patients completed the planned treatments. The total radiological response rate was 68% (32/47), including complete and partial response rates of 2% (1/47) and 66% (31/47), respectively. Stable disease was observed in 32% (15/47) and progressive disease was observed in none. Complete pathologic response, major regression, and at least moderate regression were achieved in 1 (2%), 2 (4%), and 29 (62%) patients, respectively. Four patients developed grade 3 treatment toxicities. One patient with wound infection occurred after operation (1/47, 2%). There was no treatment-related death.

Conclusions: Our results suggest that NAC with CapOX is an effective and safe treatment option for patients with locally advanced CCs.

Keywords: Colon cancer; neoadjuvant chemotherapy; phase II trial; surgery.

PubMed Disclaimer

Trial protocol (Study design).

Trial protocol (Study design).

Trial protocol (Study design).

Clinical response evaluated by CT scan.…

Clinical response evaluated by CT scan. (A) Before neoadjuvant chemotherapy; (B) After neoadjuvant chemotherapy.

Clinical response evaluated by CT scan. (A) Before neoadjuvant chemotherapy; (B) After neoadjuvant chemotherapy.

• [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].

  Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X. Ouyang GL, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):349-356. doi: 10.3760/cma.j.issn.1671-0274.2019.04.007. Zhonghua Wei Chang Wai Ke Za Zhi. 2019. PMID: 31054549 Chinese.

• Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.

  Landry JC, Feng Y, Prabhu RS, Cohen SJ, Staley CA, Whittington R, Sigurdson ER, Nimeiri H, Verma U, Benson AB. Landry JC, et al. Oncologist. 2015 Jun;20(6):615-6. doi: 10.1634/theoncologist.2015-0106. Epub 2015 Apr 29. Oncologist. 2015. PMID: 25926352 Free PMC article. Clinical Trial.

• Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.

  Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V. Fernández-Martos C, et al. J Clin Oncol. 2010 Feb 10;28(5):859-65. doi: 10.1200/JCO.2009.25.8541. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065174 Clinical Trial.

• Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II/III rectal cancer patients with low/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial).

  Shen Y, Shi W, Huang C, Gong X, Wei M, Meng W, Deng X, Wang Z; COPEC groups. Shen Y, et al. Trials. 2023 Jun 13;24(1):397. doi: 10.1186/s13063-023-07405-x. Trials. 2023. PMID: 37312165 Free PMC article.

• Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review.

  Arredondo J, Pastor E, Simó V, Beltrán M, Castañón C, Magdaleno MC, Matanza I, Notarnicola M, Ielpo B. Arredondo J, et al. Tech Coloproctol. 2020 Oct;24(10):1001-1015. doi: 10.1007/s10151-020-02289-4. Epub 2020 Jul 14. Tech Coloproctol. 2020. PMID: 32666362 Review.

• Strategies and recommendations for the management of gastrointestinal surgery during the COVID-19 pandemic: experience shared by Chinese surgeons.

  Ke J, Lan N, Wang T, Wu JJ, He Z, He XS, Tao KX, Qian Q, Zhou PH, Li GX, Zheng MH, Zhang ZT, Ji JF, Lan P. Ke J, et al. Gastroenterol Rep (Oxf). 2020 Jul 3;8(3):167-174. doi: 10.1093/gastro/goaa030. eCollection 2020 Jun. Gastroenterol Rep (Oxf). 2020. PMID: 32661490 Free PMC article.

• Neoadjuvant Chemotherapy for Colon Cancer.

  Roth MT, Eng C. Roth MT, et al. Cancers (Basel). 2020 Sep 26;12(9):2368. doi: 10.3390/cancers12092368. Cancers (Basel). 2020. PMID: 32825640 Free PMC article.

• MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma.

  Rammer M, Webersinke G, Haitchi-Petnehazy S, Maier E, Hackl H, Charoentong P, Malli T, Steinmair M, Petzer AL, Rumpold H. Rammer M, et al. Clin Exp Metastasis. 2017 Oct;34(6-7):431-440. doi: 10.1007/s10585-017-9863-9. Epub 2017 Nov 13. Clin Exp Metastasis. 2017. PMID: 29134398

• Prognostic impact of extramural venous invasion detected by contrast-enhanced CT colonography in colon cancer.

  Kato T, Tsukamoto S, Miyake M, Kudose Y, Takamizawa Y, Moritani K, Daiko H, Kanemitsu Y. Kato T, et al. BJS Open. 2024 Jan 3;8(1):zrad121. doi: 10.1093/bjsopen/zrad121. BJS Open. 2024. PMID: 38242576 Free PMC article.

• Clinical study of ultrasound and microbubbles for enhancing chemotherapeutic sensitivity of malignant tumors in digestive system.

  Wang Y, Li Y, Yan K, Shen L, Yang W, Gong J, Ding K. Wang Y, et al. Chin J Cancer Res. 2018 Oct;30(5):553-563. doi: 10.21147/j.issn.1000-9604.2018.05.09. Chin J Cancer Res. 2018. PMID: 30510367 Free PMC article.

1. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. - PubMed
2. 1. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique. 2008;56:159–75. - PubMed
3. 1. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br Med Bull. 2013;105:29–42. - PubMed
4. 1. Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. - PMC - PubMed
5. 1. Hohenberger W, Weber K, Matzel K, et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation——technical notes and outcome. Colorectal Dis. 2009;11:354–64; discussion 364-5. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3